Official Title
Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19
Brief Summary

A retrospective analysis was conducted on patients infected with the Omicron variant ofCOVID-19 diagnosed from August 2022 to now. Patients were divided into observation groupsand control groups according to whether or not oral Lianhua Qingwen granules were used.Through data analysis and follow-up, the effectiveness of Lianhua Qingwen in treatingpatients infected with the Omicron variant of COVID-19 was discussed.

Detailed Description

Not Provided

Recruiting
COVID-19 Pneumonia

Drug: The group of patients who received Lianhua Qingwen orally

Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of
treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.

Other: The group of patients who did not receive Lianhua Qingwen orally

The group of patients who did not receive Lianhua Qingwen orally.

Eligibility Criteria

Inclusion Criteria:

- For patients infected with the Omicron variant, the diagnostic criteria are
confirmed cases of COVID-19 and clinical classification according to the diagnostic
criteria of Prevention and Control Protocol for COVID-19 (Trial Eighth Edition)
issued by the National Health and Construction Commission.

- The clinical symptoms were classified as mild or ordinary.

- They have been vaccinated against the COVID-19.

Exclusion Criteria:

- Patients receiving antiviral or antibiotic drugs

- Severe and critical patients with COVID-19.

- Patients with chronic respiratory diseases, bacterial infections of the respiratory
system, and other respiratory diseases affecting the study.

- Patients with serious primary diseases of the heart, brain, lung, liver, kidney, and
hematopoietic systems, as well as mental diseases.

- Allergic reaction to Lianhua Qingwen granules.

- Excluded patients treated with the same drug as Lianhua Qingwen.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 80 Years
Countries
China
Locations

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
Jinan, Shandong, China

Investigator: Qian Qi, Dr.
Contact: +86 13706380314
qiqianqlh@163.com

Contacts

Qian Qi, Dr.
+86 13706380314
qiqianqlh@163.com

Not Provided

Qianfoshan Hospital
NCT Number
MeSH Terms
COVID-19